ARTICLE
The NAKED Truth about Trademark Cancellation: Only Harm, no Proprietary Interest Required
August 26, 2020
Read time: 1 min

ARTICLE
August 26, 2020
Read time: 1 min

ARTICLE
August 26, 2020
Read time: 1 min

ARTICLE / CLIENT ALERT
August 20, 2020
Read time: 6 min
One day before an updated rule of the US Department of Health and Human Services regarding Section 1557 of the Patient Protection and Affordable Care Act took effect, the US District Court for the Eastern District of New York ordered a stay and issued a preliminary injunction precluding the most recent final rules from becoming operative. Entities subject to Section 1557 should — at least until decisions are issued in cases pending in US district courts — be cautious in their approach to their non-discrimination compliance obligations.
“When the Supreme Court announces a major decision, it seems a sensible thing to pause and reflect on the decision’s impact.” These words from Senior United States District Judge Frederic Block concisely summarize advice given by the US District Court for the Eastern District of New York in the case of Walker v. Azar. The court issued its order on August 17, 2020, the day before the effective date of the US Department of Health and Human Services’ (HHS) rule regarding Section 1557 of the Patient Protection and Affordable Care Act (ACA) and how “on the basis of sex” should be interpreted in Section 1557. In granting a stay and issuing a preliminary injunction precluding the most recent final rules under Section 1557 from becoming operative, Judge Block cited the US Supreme Court’s landmark 6-3 Bostock decision (see our On The Subject here), which held that discrimination based on sex encompassed discrimination based on both sexual orientation and gender identity in the employment context (Title VII of the Civil Rights Act of 1964).
Background
In 2016, HHS published a final rule that interpreted “sex” broadly, barring providers that receive federal funding from discriminating on the basis of gender identity, gender expression, sex stereotyping and pregnancy-related conditions pursuant to Section 1557 of the ACA (the 2016 Final Rules). Almost immediately, the US District Court for the Northern District of Texas enjoined enactment of that portion of Section 1557, stating that HHS exceeded its authority to define discrimination on the basis of sex in such a way. On May 24, 2019, HHS promulgated new rules repealing the definitions section of Section 1557 “in order to make [HHS’] regulations implementing Title IX through the Section 1557 Regulation more consistent with the Title IX regulations of other Federal agencies.” As we reported previously, on June 19, 2020, HHS published rules under Section 1557 of the Affordable Care Act (the 2020 Final Rules) that, among other things, rescinded certain protections afforded to LGBTQ individuals. However, as part of the 2020 Final Rules, HHS included a lengthy preamble reiterating its position that “Title VII and Title IX do not encompass discrimination on the basis of sexual orientation or gender identity.”
Walker et al v. Azar
On June 26, 2020, the Human Rights Campaign in the US District Court for the Eastern District of New York filed a lawsuit on behalf of two transgender women of color, contesting HHS’s interpretation of “on the basis of sex.” The plaintiffs sought a stay and preliminary injunction, asking the court to declare that the 2020 Final Rules were invalid under the Administrative Procedure Act, to vacate the 2020 Final Rules, to stay the effective date of the 2020 Final Rules and to enjoin HHS from enforcing them preliminarily.
The Walker court’s order found that the plaintiffs had standing and determined that the 2020 Final Rules were contrary to law and that HHS acted arbitrarily and capriciously by promulgating the 2020 Final Rules. The definitions section from the 2016 Final Rules, codified at 45 C.F.R. § 92.4, had defined “because of sex” to include discrimination “on the basis of pregnancy, false pregnancy, termination of pregnancy, or recovery from, childbirth or related medical conditions, sex stereotyping, or gender identity.” But HHS said in the preamble to the 2020 Final Rules that it disagreed with the 2016 Final Rules’ interpretation of “because of sex” and instead followed the position in EEOC v. R.G. & G. R Harris Funeral Homes that “Title VII and Title IX does not encompass discrimination ‘on the basis of’ sexual orientation or gender identity.” Notably, Harris Funeral Homes was ultimately consolidated with Bostock.
HHS argued to the court that Title VII case law often informs Title IX matters involving discrimination because of sex. However, the Walker court articulated a concern that HHS was finalizing the 2020 Final Rules without discussing the impact of the Bostock decision. The court was careful to note that Bostock and other Title VII cases are not dispositive in cases regarding Title IX discrimination “because of sex.” However, by failing to address Bostock, the court “conclude[d] that the proposed rules are, indeed, contrary to Bostock and, in addition, that HHS did act arbitrarily and capriciously in enacting them. Therefore, [the court] grant[ed] plaintiffs’ application for a stay and a preliminary injunction to preclude the rules from becoming operative.”
Application
Ultimately, the court stayed the repeal of the 2016 definition of discrimination on the basis of sex and preliminarily enjoined HHS from enforcing the repeal. As a result, the definitions of “on the basis of sex,” “gender identity” and “sex stereotyping” remain in effect. A plain reading of the court’s decision would indicate that the preliminary injunction only applies to the definition of “on the basis of sex,” meaning that the rest of the 2020 Final Rule will remain in effect, including the rollback of certain regulatory burdens. This sort of surgical relief by courts is not uncommon in lawsuits under the Administrative Procedure Act. However, because of some ambiguity in the court’s holding, some practitioners believe that the preliminary injunction applies to the entirety of the 2020 Final Rule, enjoining the entire rule from taking effect. Entities subject to Section 1557 should be cautious in their approach and interpretation of Walker as it relates to their compliance obligations.
We anticipate that additional clarification will be forthcoming on the current status of Section 1557 and the breadth of the Walker court’s order when decisions are issued for cases currently under review in the US District Court for the District of Columbia and the US District Court for the Western District of Washington.

ARTICLE
August 11, 2020
Read time: 6 min
Many employers who recently reopened are now facing a new challenge—employee off-duty conduct. At stake is both workplace and customer safety as well as the company’s reputation. Our recent webinar discussed different scenarios that employers are likely to face and how to practically navigate and mitigate any potential risks when responding to off-duty conduct issues.
View the full webinar here.
You run an essential business manufacturing company in Naperville, Illinois, that is currently in Phase 4 of COVID reopening that bans gatherings of more than 50 people. Iowa allows large gatherings with no restrictions. It gets brought to your attention that over the weekend John Smith from the maintenance group attended a political protest in Iowa with 150 other people. John is set to return to work on Tuesday. Do you make John quarantine for two weeks before returning to work?
What is your opinion on whether you would need to pay John if he were exempt in the event that you required him to quarantine?
This depends on a few things. If the employee is exempt and is working remotely during quarantine, then he/she should be paid. If the employee is exempt and not working remotely during quarantine, then he/she should be paid for the full salary for any week in which the employee performs any work. Assuming that the employee is not entitled to FFCRA paid leave, it would be permissible to withhold pay for any week in which the employee performs no work.
Doesn’t FFCRA require two weeks’ pay for quarantine mandated by the City of Chicago under your example? Is it not required in Naperville if the employee is forced to quarantine?
The Naperville example was meant to illustrate the difference between the City of Chicago, which has a mandatory 14-day quarantine for individuals traveling to Chicago from certain states, and Naperville which has no such mandatory quarantine. You are correct that any quarantine should consider whether the employee is entitled to paid leave under the FFCRA or other applicable laws.
What about commuting scenarios, where employees work in one state and live in another, traveling back and forth on a daily basis?
This will depend on the specific state and that state’s restrictions for quarantine related to travel from outside states. If, for example, the employee lived in Wisconsin and commuted to Chicago every day, then the Chicago order would mandate a 14-day quarantine. The commute might also require varying obligations regarding the wearing of masks while driving or when entering and exiting the vehicle or the number of people in a car.
Are racist statements protected as “political” speech/activities?
Generally speaking, no. Racist comments are not covered as political speech/activities, and employers can discipline employees for such conduct.
Can an employer provide that an employee cannot use a competitor’s product? Can the employee be fired for a Facebook picture that shows the employee using the competitor’s product?
This will depend on the specific facts of the situation, but in general, we would not recommend that employers discipline employees for using a competitor’s product.
An acquaintance returns to New York from Florida and returns to work immediately (no quarantine) in the grocery business. What liability/responsibility does the employer have to determine the facts/enforce quarantine?
Once brought to the employer’s attention, the employer should investigate to determine whether the employee did travel to Florida. Assuming that the employee did travel to Florida, he/she would be subject to a 14-day quarantine per the New York guidance.
You recently told your employees that your company, ABC Corp., is going to make a concerted effort to promote diversity in the workplace, including by seeking to promote women and minorities. An employee, Josephine, tells you she is offended by her colleague John’s recent Facebook post: “ABC Corp. says it will only promote women and minorities, even though white men like me are almost always more qualified. Isn’t that discrimination?” Can you discipline John for disparaging ABC Corp. online? What about for offending Josephine?
What about statements that do not align with a Company’s mission or stance on particular issues? Can we discipline if such statements are stated outside of work on public channels?
This will depend on the specific statement at issue. For example, a Company could potentially discipline for racist public statements that are against a Company’s mission or stance on a diversity initiative. For a statement that is generally disagreeing with a general mission statement, you will need to consider whether the statement violates any of your current policies and whether the employee’s conduct is lawful, in which case it may be protected by certain states’ laws.
You recommend a “narrow” policy. Can you provide an example of a policy that is not narrow?
A policy that attempts to regulate off-duty political activity or all lawful off-duty conduct is likely too broad and in violation of multiple states’ laws.
Is social media (e.g., Facebook or Twitter, etc.) a “lawful product”? Or is use of it “lawful conduct”?
It is lawful conduct to make social media posts, but keep in mind that some states that prohibit adverse actions for lawful conduct outside of work also have carve-outs for actions that are against business-related interests (for example, North Dakota and Utah).
What if the employee says All Lives Matter, rather than Black Lives Matter?
On its face, this comment is unlikely to violate a typical employer’s harassment or anti-discrimination policy.
What about intolerance, racist or discriminatory activity or posts? Based on some early examples, some companies are acting decisively and swiftly.
We are generally seeing employers discipline employees, including up to termination, for making racist or discriminatory comments or social media posts.

ARTICLE / CLIENT ALERT
August 20, 2020
Read time: 9 min
The August 6, 2020, Executive Order on Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States directs the FDA and other federal agencies to take actions that could expand future procurement opportunities for pharmaceutical manufacturers and members of the medical supply chain, while restricting opportunities for others.
On August 6, 2020, President Donald Trump issued the Executive Order on Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States. The Executive Order is aimed at ensuring that there is an adequate supply in the United States of Essential Medicines, Medical Countermeasures, and Critical Inputs (i.e., the ingredients and components used to make essential medicines and medical countermeasures) (collectively, “Products”) in the face of chemical, biological, radiological and nuclear threats and public health emergencies, such as infectious disease outbreaks. The Order establishes a policy of decreasing reliance on foreign manufacturers for Products by 1) increasing the development of domestic production of Products and developing an adequate redundancy in the domestic supply chain; 2) ensuring long-term demand for US-made Products; 3) focusing on domestic production capabilities for critical inputs, finished drug products and finished devices essential for public safety and national defense; and 4) combating counterfeit Products on e-commerce platforms and third-party online sellers involved in government procurement.
To achieve these goals, the Order sets forth requirements for executive departments and agencies involved in the procurement of Products, as described below.
What Does the Order Mean for Federal Contractors?
The President’s Order requires various federal agencies to take actions that could significantly boost future procurement opportunities for certain federal contractors, while restricting opportunities for others. While the Order is likely to have near-term impacts on federal contractors, its impact will likely continue to evolve as the relevant federal agencies carry out the Order’s directives and issue the required recommendations and reports.
Federal contractors that are domestic producers of Products could see increased opportunities due to the Order’s directive to federal agencies to limit competition to Products produced in the United States, as well as the Order’s directive that agencies divide procurement requirements among two or more manufacturers. This could have significant competitive ramifications for existing contractors that can meet the Order’s requirements related to domestic manufacturing. Further, the Secretary of Health and Human Services, through the US Food and Drug Administration (FDA) Commissioner, is directed to accelerate FDA approval or clearance for such domestic producers of Products.
On the other hand, these same directives could significantly limit opportunities for contractors that do not produce Products domestically and have traditionally relied upon existing statutory guidance that permits compliance with ordinary Buy American Act requirements through the Trade Agreement Act. The Order’s directive to the US Trade Representative to exclude coverage of products from the US federal procurement under all relevant Free Trade Agreements and the World Trade Organization Agreement on Government Procurement could further reduce opportunities for federal contractors that are not domestic producers.
Additionally, when considered necessary for national defense reasons, the Secretary of Defense is directed to use his authority under the Defense Federal Acquisition Regulation Supplement (DFARS) to restrict procurement of Products to domestic sources and reject otherwise acceptable offers from Qualifying Countries. A trend towards this activity has been evident in certain procurements and is worth examining when planning for manufacturing capabilities and engagement with subcontractors for manufacturing needs.
How Will FDA Modify Its Procedures?
On its face, the Order is an unfunded mandate for the FDA, requiring the agency to engage in at least some activities that it normally does not, and which fall within the practice of medicine or more traditionally with other public health agencies such as the Centers for Disease Control and Prevention or medicine manufacturers themselves. For instance, the FDA does not normally identify “essential” medicines and countermeasures, but it does identify products that would qualify for a priority review to fill an unmet treatment need. The FDA can help accelerate the review or clearance of products by providing increased input during development and by placing priority on the review cycles, but it is not accustomed to prioritizing a “made in the USA” approach. Given that many medicines sold in the United States currently are made with ingredients or components from overseas, it will take time for companies to develop economically viable capacities to make all of those ingredients and components domestically. Just as the FDA does not normally identify products made solely with domestic ingredients and components, the agency does not usually identify supply chain issues for manufacturers. This responsibility is expected to fall to the manufacturers themselves.
The Order further requires the FDA to increase the frequency of foreign inspections, where the agency has been implementing a prioritization process to inspect facilities with more deficiencies more often. Together, these new requirements may place a further strain on the FDA’s tight resources, which have been constrained by COVID-19, and could reduce, or in many cases eliminate, the FDA’s ability to conduct routine or for-cause inspections. The FDA therefore will likely require more resources to take on these new responsibilities, a factor that the Order does not seem to have contemplated.
We will continue to track how this Order affects federal contractors, the FDA and the supply chain in general, and will provide an update when the impact can be better ascertained.
Immediate Agency Actions Requested
Within 90 Days of the Date of This Order (by November 4, 2020)
Exceptions
The requirements above do not apply where the head of agency determines the following:
If the head of agency makes any of the determinations above, she must submit an annual report to the President describing the justification for the determination.
The requirements also do not apply if the Products are necessary to respond to any public health emergency, major disaster or national emergency.
Within 180 Days of the Date of This Order (by February 2, 2021)
No Later than December 15, 2021 and Annually Thereafter

ARTICLE / CLIENT ALERT
August 20, 2020
Read time: 5 min
On August 17, 2020, the Centers for Medicare and Medicaid Services (CMS) announced in a memo to State Survey Agency Directors (QSO-20-35-ALL) the resumption of certain routine surveys and inspections of healthcare providers and suppliers, including on-site complaint investigations, surveys and revisits/revalidations, once sufficient staff and necessary personal protective equipment are available.
In March 2020, during the initial response to the coronavirus (COVID-19) public health emergency (PHE), CMS first prioritized (QSO-20-12-ALL) and then severely restricted (QSO-20-20-ALL) all survey activity aside from certain high-priority surveys, which included infection control surveys and the investigation of complaints and incidents alleging immediate jeopardy (IJ) to patient health and safety. Most enforcement actions were also suspended at that time. CMS’s latest guidance comes after a more limited expansion of survey activities in June, when the agency issued re-prioritization guidance (QSO-20-31-ALL) that directed states to resume certain surveys for all provider and supplier types once they had reached Phase 3 of CMS Nursing Homes Reopening Recommendations for State and Local Officials (QSO-20-30-NH), or earlier at the state’s discretion.
In addition to directing the resumption of additional on-site survey activity for long-term care facilities, this most recent CMS guidance encourages states to resume normal survey activity for other types of providers once the states reach Phase 3 of the Administration’s “Opening Up America Again” guidance for state/regional reopening (or earlier at their discretion), following the survey priorities set forth in the CMS FY 2020 Mission & Priority document. States are also encouraged to work through the backlog of surveys postponed because of the PHE. States are to work with their local CMS offices to prepare a proposed timeframe for completion of these surveys.
CLIA Labs
QSO-20-35-ALL also announced CMS re-prioritization guidance for survey activities associated with Clinical Laboratory Improvement Amendments (CLIA) labs. In particular, CMS recommends that states resume most on-site surveys and proceed with enforcement actions or PT desk reviews that have been on hold. These lab-focused recommendations are subject to state discretion and each state’s “unique COVID-19 restrictions and safety precautions.”
Plan of Action to Resolve Suspended Provider Enforcement Actions
In its March 2020 guidance in QSO-20-20-ALL, CMS announced a period of enforcement discretion during which it suspended provider enforcement actions except for those related to unremoved IJs, and stayed accrual of certain related financial penalties for long-term care providers. CMS has now established a process to begin resolving these enforcement actions, depending on the date and stage of the enforcement action. In QSO-20-35-ALL, CMS provides that state survey agencies may review plans of corrections (POCs) via an “expanded desk review” and without an on-site survey (except for unremoved IJs) for those enforcement actions that were started between March 23 and May 31, 2020, under which providers were permitted to delay their submission of a POC. Under this new process, providers will generally have 10 calendar days to submit their POCs and supporting evidence for any such surveys that ended prior to June 1, 2020. Normal POC submission processes and on-site revisits are authorized for surveys that end on or after June 1, 2020. Providers in areas where there is a current COVID-19 outbreak may request extensions to the POC submission timeline.
The new CMS guidance details the different ways in which the agency will proceed to resolve provider and supplier enforcement cases that fall into three categories: those (1) initiated prior to March 23, 2020; (2) initiated between March 23 and May 31, 2020; or (3) initiated on or after June 1, 2020. Civil monetary penalties (CMPs) and denials of payment for new admissions will be calculated differently for each of these categories, and CMP due dates will be adjusted. In addition, CMPs will not be imposed for noncompliance below the Actual Harm or IJ levels for enforcement cycles that started between March 23 and May 31, 2020.
Key Takeaways
Providers and suppliers should prepare for the immediate possibility of on-site survey activity and the resumption of any suspended survey or enforcement processes that started before or during the early stages of the PHE. Where current COVID-19 outbreaks restrict the resources available to complete POCs, extensions of time to submit may be granted on a case-by-case basis. Notwithstanding this flexibility, the most recent CMS guidance signals that the “next normal” for all provider types will include a near-term return to robust survey activity through a combination of expanded desk reviews and on-site surveys, and a resumption in suspended and new enforcement actions.
ARTICLE
August 19, 2020
Read time: 1 min

ARTICLE / CLIENT ALERT
August 17, 2020
Read time: 9 min
Cybercriminals are targeting businesses of all kinds with ransomware attacks. As these attacks become more sophisticated, carrying the potential to effect a wholesale inability to access a firm’s entire electronic infrastructure, ransom demands have increased — often reaching eight figures. Because these denial of access attacks have been so effective, making ransom payments has become mainstream in corporate America.
Private fund managers may be particularly attractive targets. Firms that are active traders could face potentially large trading losses if locked out of their systems. Firms that buy controlling stakes in companies could face ransomware attacks at both the manager and portfolio company levels.
With the recent surge in ransomware incidents, driven in part by vulnerabilities created due to the COVID-19 pandemic,[1] it is more important than ever for fund managers to take steps to safeguard their systems and data against an attack. Recent alerts from the SEC’s Office of Compliance Inspections and Examinations (“OCIE”) and the U.S. Department of Homeland Security’s Cybersecurity and Infrastructure Security Agency (“CISA”) underscore the importance of preparedness and operational resiliency in contending with the threat of ransomware attacks.
Ransomware is a type of malware designed to block an organization’s access to its information systems, and/or permit unauthorized access to potentially sensitive data, until a ransom is paid. Ransomware perpetrators typically demand a ransom in exchange for returning control over the compromised systems to the organization and/or agreeing to not publicly disclose or use the data accessed.
There are numerous routes ransomware can take to access a firm’s computers. Phishing scams are one of the most common delivery methods of malware used to propagate ransomware attacks. Phishing messages employ a combination of legitimate business names and domains, professional terminology and language implying urgency to deceive recipients as to the validity of the messages and to activate attachments.
Private fund managers may be inviting targets for these attacks. Managers may be seen as financially attractive targets — deep pockets by cybercriminals seeking six- and seven-figure ransoms. Further, the public disclosures required of managers can, in some cases, be fertile ground for the types of information cybercriminals use to prey on targets. For example, the identification of the names of senior management personnel could assist cybercriminals in identifying individuals to target.
As with other businesses, ransomware attacks can wreak havoc on fund managers in a variety of ways, some of which are more obvious than others. While attacks on administrators and other service providers who retain the fund’s books and records risk compromising sensitive information stored by the vendor, ransomware attacks that include a “denial of service” component have the potential for even more disturbing consequences. In these attacks, the cybercriminal encrypts or otherwise blocks access to a firm’s information systems, rendering these systems unusable.[2] This leaves a fund manager unable to carry out basic functions. For an active trading firm, for example, the prospect of being unable to view a portfolio or to trade or hedge positions for even a portion of a trading day could be untenable. However, all categories of fund managers should be implementing safeguards to mitigate the risk of ransomware attacks (some strategies for doing so are discussed below).
Of course, vendor diligence and cooperation remains an important part of the landscape. A recent attack on the vendor of a fund administrator, for example, exposed the personal information of investors for a large number of the administrator’s fund clients.[3] While, in these instances, the service provider contends with the attack while it is happening, upon notification of the attack from the administrator, fund managers are left to evaluate and address the potential for legal obligations and reputational harm as a result of the attack.
Recommendations from Regulators
The risks presented by ransomware attacks have not gone unnoticed by regulators. On July 10, 2020, OCIE released an alert[4] urging managers (and other registrants) to familiarize themselves with the risks of ransomware attacks and to prepare their internal systems to prevent, repel and mitigate attacks. The OCIE alert provides examples of measures to be considered and recommends that market participants monitor CISA’s cybersecurity alerts. In an Aug. 12, 2020 OCIE alert focused on COVID-19 compliance risks, the OCIE echoed concerns over cybersecurity attacks and provided similar guidance for maintaining effective policies and procedures.
The specific actions recommended by OCIE and CISA to bolster institutional protection against ransomware attacks include, among others, the following:
For the most current guidelines and recommendations on avoiding and protecting against a ransomware attack, fund managers should periodically review the “Cybersecurity Spotlight” webpage maintained by OCIE, which contains related guidance and resources.
Insights for Institutional Preparedness
While the individual recommendations are useful criteria to analyze, the key takeaway from the OCIE and CISA guidance is that cybersecurity efforts and, in particular, steps designed to protect a manager from a ransomware attack, are as much a part of a private fund manager’s compliance obligations as the need to take steps to prevent crimes such as insider trading. Among other things, this means fund managers should be:
Authored Brian T. Daly, Marc E. Elovitz, Edward H. Sadtler, Kelly Koscuiszka, Jennifer A. Gordon and Jaclyn N. Malmed.
If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.
[1] In a recent advisory, the U.S. Department of the Treasury’s Financial Crimes Enforcement Network (“FinCEN”) identified the migration of businesses to remote access during the COVID-19 pandemic, and the resulting potential for system vulnerability, as a key reason for the substantial increase in ransomware and other cybersecurity attacks on financial institutions’ remote systems.
[2] In a recent example reported by WIRED and other popular media, Garmin, a manufacturer of fitness-oriented devices and wearables, experienced an attack in which a cybercriminal employed a ransomware attack to encrypt Garmin’s systems, resulting in a complete shutdown of user access to Garmin’s systems. Garmin is believed to have paid a multimillion-dollar ransom to avoid a protracted disruption to its business.
[3] A Wall Street Journal article reporting on the breach noted that it was the latest in a string of attacks that have affected financial service companies through their vendors.
[4] The OCIE alert warns about the increased sophistication of cybersecurity attacks on SEC registrants. As with recent news articles, OCIE reported that cybercriminals have been orchestrating phishing campaigns and other cybersecurity attacks designed to penetrate the networks of financial institutions (including private fund managers) to gain access to internal resources and deploy ransomware, among other objectives.
[5] Fund managers should advise their employees to be aware of emails coming from seemingly legitimate sources referencing common subject and attachment titles, including “invoice,” “scan,” “debit note” or similar terms. The body of phishing emails may be blank or comprehensive, potentially referencing that the email has already undergone a malware or virus scan. When clicking links or opening email attachments, verify that the domain names in both the sender’s email address and any included hyperlinks are spelled correctly. FinCEN’s recent advisory delineates red flag indicators of COVID-19-related cyber scams.
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.
All rights reserved . SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

ARTICLE / CLIENT ALERT
August 13, 2020
Read time: 6 min
A bipartisan pair of US senators have proposed legislation that would allow certain controlled substances to be prescribed via an initial telehealth encounter and—under certain conditions—expand Medicare reimbursement of audio-only substance use disorder treatment services. The proposed TREATS Act has been referred to the Senate Committee on Health, Education, Labor, and Pensions, and could significantly reduce the regulatory burdens associated with the remote prescribing of controlled substances.
For more than a decade, healthcare providers in the United States have been largely prohibited from prescribing controlled substances via telehealth without having previously performed an in-person medical evaluation of the patient. Although Congress created the framework for a “special registration” pathway that has the potential to more broadly permit the practice, the Drug Enforcement Administration (DEA) has not issued regulations to implement it. This has been a significant roadblock for the treatment of substance use disorder, which is often treated with controlled substances. Recently, Senators Rob Portman (R-OH) and Sheldon Whitehouse (D-RI) proposed the Telehealth Response for E-prescribing Addiction Therapy Services Act (the TREATS Act), which would allow certain controlled substances to be prescribed via telehealth. The TREATS Act also proposes to expand Medicare reimbursement of audio-only substance use disorder treatment services, if certain conditions are met. The TREATS Act was introduced on June 30, 2020, and has been referred to the Committee on Health, Education, Labor, and Pensions.
Remote Prescribing of Schedules III and IV Controlled Substances
The remote prescribing of controlled substances has been stymied by the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (the Ryan Haight Act), which typically requires providers to perform an in-person medical evaluation of the patient prior to prescribing controlled substances. The Ryan Haight Act does incorporate seven pathways by which practitioners can prescribe controlled substances via telemedicine without a prior in-person examination, but these exceptions are extremely narrow and it is difficult for most providers to meet their requirements. One of the pathways, however, called for a “special registration process” that had the potential to more broadly permit providers to prescribe controlled substances via telemedicine. Congress left the implementation of the special registration process up to the DEA—and the DEA never issued regulations to implement it. After ten years of silence, Congress again pushed the DEA to act, imposing a second deadline for the DEA to implement regulations regarding the special registration process by October 24, 2019, under the SUPPORT for Patients and Communities Act. While there were rumblings that the DEA was prepared to act in late 2019, it is still yet to issue a proposed rule regarding the special registration process.
As we explained in a prior On the Subject, the COVID-19 public health emergency ushered in a significant, albeit temporary, change to the Ryan Haight Act, permitting providers to prescribe controlled substances via telehealth without a prior in-person medical evaluation during the pendency of the public health emergency declared by the Secretary of Health and Human Services. As a result, since March 16, 2020, DEA-registered practitioners have been able to prescribe controlled substances without an in-person medical evaluation of the patient, as long as they conduct a telehealth evaluation using audio-visual, real-time, two-way interactive communications.
The TREATS Act would make this flexibility permanent in certain circumstances, permitting providers to prescribe controlled substances in Schedules III and IV on the basis of a telehealth evaluation. While Senators Portman and Whitehouse introduced the bill largely to expand the use of telehealth to treat substance use disorder, it would have broader ramifications because the bill (as proposed) would apply to all Schedule III and IV controlled substances, regardless of the reason for which the substances are prescribed. Under the bill’s current language, the telehealth evaluation would have to be provided via audio and video equipment permitting two-way, real-time communication, and it would otherwise have to comply with applicable state and federal laws. Certain state laws may still limit prescribing of controlled substances, as many states regulate remote prescribing of controlled substances even more strictly than the federal government; in some cases, states prohibit the practice altogether.
Audio-Only Substance Use Disorder Treatment Services
In addition to the relaxation of remote prescribing of Schedules III and IV controlled substances, the TREATS Act also seeks to expand Medicare’s reimbursement of audio-only substance use disorder treatment services. Specifically, the TREATS Act would permit audio-only services to be reimbursed if the treating practitioner had already conducted an in-person evaluation of the patient or a telehealth evaluation that uses both audio and visual services.
The proposal to reimburse audio-only substance use disorder treatment services represents a significant deviation from the current regulatory environment. Although the Centers for Medicare and Medicaid currently permits some Medicare reimbursement of audio-only telehealth services because of the COVID-19 pandemic (and, as described in another On the Subject , is currently seeking comment in the 2021 Physician Fee Schedule proposed rule about whether to continue to pay for audio-only telephone evaluation and management services), it has historically only reimbursed for telehealth visits that take place using audio and video equipment that incorporate a live, two-way interactive communication between the practitioner and the provider because of statutory limitations. Moreover, many states—which often have more liberal telehealth policies than the federal government—explicitly exclude audio-only telephone services from their definition of telehealth or telemedicine. Accordingly, it would be a fairly significant policy shift if Congress began to permit the reimbursement of audio-only services to treat substance use disorder

ARTICLE / CLIENT ALERT
August 13, 2020
Read time: 16 min
On August 4, 2020, the Centers for Medicare and Medicaid Services (CMS) released a proposed rule to update its payment policies under the Medicare Physician Fee Schedule (PFS) for calendar year 2021. The proposed rule was issued in tandem with a presidential executive order, which directed the Secretary of the US Department of Health and Human Services (HHS) to propose regulations expanding telehealth services covered by Medicare. CMS stated that the proposed rule “is one of several proposed rules that reflect a broader Administration-wide strategy to create a health care system that results in better accessibility, quality, affordability, empowerment, and innovation.”
In response to the coronavirus (COVID-19) public health emergency (PHE), CMS has issued several temporary waivers and flexibilities that expand telehealth reimbursement under Medicare, Medicaid and the Children’s Health Insurance Program for the duration of the COVID-19 PHE. CMS issued these waivers under authorities granted pursuant to HHS’s public health declaration, as well as legislation passed in response to the pandemic. Many of these waivers have substantially altered the Medicare telehealth reimbursement landscape and, as we detailed in our prior On the Subject, many can be made permanent via regulatory action. The proposed rule represents the first official word that CMS will take such action to make certain of its waivers permanent. These policy changes have the potential to greatly increase the availability of telehealth to Medicare beneficiaries around the country.
CMS will accept comments, either electronically or by mail, on the proposed rule until 5 pm EDT on October 5, 2020.
Changes to Medicare Telehealth Services
CMS proposed to add several services, listed below, to its list of services that may be delivered via telehealth. Many of these were previously added on an interim final rule basis for the duration of the PHE. The proposed rule would keep them on the Medicare telehealth services list even after the PHE ends.
CMS also proposed a new method for adding or deleting services from the Medicare telehealth services list. Currently, CMS evaluates new services for inclusion based on two categories: Category 1 is for services that are similar to professional consultations, office visits and office psychiatry visits that are already on the Medicare telehealth services list, while Category 2 is for services that are not similar to those already on the list, but that would still be appropriate to include because the service is accurately described by the corresponding code when delivered via telehealth and providing the service via a telecommunications system results in clinical benefit for the patient. Because of the COVID-19 PHE, CMS has proposed to add a Category 3, which would include services that would be temporarily on the Medicare telehealth services list. CMS proposed this third category because, while CMS currently has the authority to waive or modify Medicare telehealth payment requirements during the PHE, that authority will expire once the PHE ends. And once the PHE expires, Medicare payment policy will return to the most recently established Medicare telehealth services list, which would not include many of the services temporarily added to the list for the duration of the PHE.
CMS proposed that Category 3 would include telehealth services that were added to the list during the PHE and for which there is likely to be a clinical benefit when delivered through telehealth but there is not currently sufficient evidence to permanently add the service based on the Category 1 or Category 2 criteria. Services added through the Category 3 pathway would remain on the Medicare telehealth services list through the end of the calendar year in which the PHE ends.
Services Proposed to Permanently Remain on the Medicare Telehealth Services List
| HCPCS CODE | Long Descriptor |
| GPC1X | Visit complexity inherent to evaluation and management associated with primary medical care services that serve as the continuing focal point for all needed health care services (Add-on code, list separately in addition to an evaluation and management visit) |
| 90853 | Group psychotherapy (other than of a multiple-family group) |
| 96121 | Neurobehavioral status exam (clinical assessment of thinking, reasoning, and judgment, [e.g., acquired knowledge, attention, language, memory, planning and problem-solving, and visual-spatial abilities]), by physician or other qualified health care professional, both face-to-face time with the patient and time interpreting test results and preparing the report; each additional hour (List separately in addition to code for primary procedure) |
| 99XXX | Prolonged office or other outpatient evaluation and management service(s) (beyond the total time of the primary procedure which has been selected using total time), requiring total time with or without direct patient contact beyond the usual service, on the date of the primary service; each 15 minutes (List separately in addition to codes 99205, 99215 for office or other outpatient Evaluation and Management services) |
| 99483 | Assessment of and care planning for a patient with cognitive impairment, requiring an independent historian, in the office or other outpatient, home or domiciliary or rest home, with all of the following required elements: Cognition-focused evaluation including a pertinent history and examination; Medical decision making of moderate or high complexity; Functional assessment (e.g., basic and instrumental activities of daily living), including decision-making capacity; Use of standardized instruments for staging of dementia (e.g., functional assessment staging test [FAST], clinical dementia rating [CDR]); Medication reconciliation and review for high-risk medications; Evaluation for neuropsychiatric and behavioral symptoms, including depression, including use of standardized screening instrument(s); Evaluation of safety (e.g., home), including motor vehicle operation; Identification of caregiver(s), caregiver knowledge, caregiver needs, social supports, and the willingness of caregiver to take on caregiving tasks; Development, updating or revision, or review of an Advance Care Plan; Creation of a written care plan, including initial plans to address any neuropsychiatric symptoms, neuro-cognitive symptoms, functional limitations, and referral to community resources as needed (e.g., rehabilitation services, adult day programs, support groups) shared with the patient and/or caregiver with initial education and support. Typically, 50 minutes are spent face-to-face with the patient and/or family or caregiver. |
| 99334 | Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient’s and/or family’s needs. Usually, the presenting problem(s) are self-limited or minor. Typically, 15 minutes are spent with the patient and/or family or caregiver. |
| 99335 | Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient’s and/or family’s needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 25 minutes are spent with the patient and/or family or caregiver. |
| 99347 | Home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient’s and/or family’s needs. Usually, the presenting problem(s) are self limited or minor. Typically, 15 minutes are spent face-to-face with the patient and/or family. |
| 99348 | Home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient’s and/or family’s needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 25 minutes are spent face-to-face with the patient and/or family. |
Furnishing Telehealth Visits in Inpatient and Nursing Facility Settings
CMS requires that residents of skilled nursing facilities receive an initial visit from a physician and subsequent periodic personal visits from either a physician or a nonphysician practitioner (NPP). Historically, physicians and NPPs were prohibited from performing those visits via telehealth, but CMS issued a waiver that permitted such visits to be performed via telehealth for the duration of the PHE. CMS now seeks comment on whether it should extend this flexibility beyond the PHE.
CMS also noted that it has received requests to remove frequency limitations on the number of subsequent inpatient visits that can be conducted via telehealth. CMS announced that it would not propose to modify this policy, on the grounds that in-person care is preferable “to facilitate the comprehensive, coordinated, and personal care that medically volatile, acutely ill patients require on an ongoing basis.”
That said, CMS proposed to revise the limit on providing subsequent nursing facility visits via telehealth from once every 30 days to once every three days. CMS said that it was persuaded by stakeholder comments that this limitation hinders access to care and that clinicians should have the authority to determine how often their patients should receive visits via a Medicare telehealth service.
Communication-Technology-Based Services
In the March 31, 2020, interim final rule for the Medicare and Medicaid programs, CMS announced that certain NPPs, consistent with their respective benefit category, could bill HCPCS codes G2061 through G2063 for the duration of the PHE. These HCPCS codes, which include services such as online assessment and management for an established patient for up to seven days, could be billed by licensed clinical social workers, clinical psychologists, physical therapists, occupational therapists and speech-language pathologists. CMS has now proposed to adopt these policies permanently. Notably, this is not an exhaustive list, and CMS seeks comments on other benefit categories into which these services fall.
CMS proposed to allow billing of other communication-technology-based services by certain NPPs through the creation of two additional telehealth codes:
CMS recognized that it previously valued similar services differently based on who can and cannot bill independently for office/outpatient E/M services, with higher values placed on practitioners who can independently bill E/M services. CMS noted that similar check-ins provided by nurses and other clinical staff could be important aspects of coordinated patient care, and thus CMS proposed to value codes G20X0 and G20X2 identically to other physician telehealth check-in codes G2010 and G2012. To further facilitate the billing of communication-technology-based services by therapists, CMS proposed to designate HCPCS codes G20X0, G20X2, and G2061 through G2063 as “sometimes therapy” services.
Practitioners must continue to obtain patient consent so that patients are mindful of their co-pay obligations when receiving these services. CMS does not believe that the timing or manner in which patient consent is acquired should interfere with the delivery of brief communication-technology-based services. Further, a patient’s consent to receive these services can be documented by auxiliary staff under general supervision, as well as by the billing practitioner.
Direct Supervision
CMS recognizes that, in some instances, technology allows appropriate supervision without the physical presence of a physician (or other supervising practitioner) when a service or procedure is performed. CMS adopted an interim final policy revising the definition of direct supervision to include virtual presence using interactive audio and video technology for the duration of the PHE to reduce exposure risk to the supervising practitioner, and CMS has now proposed to extend this policy until the end of the calendar year in which the PHE ends, or December 31, 2021, whichever is later. CMS opted to do so because it recognizes that the unique circumstances faced by individual communities may continue after the PHE ends, and extending this policy provides time to solicit public input on situations where the flexibility to use real-time audio and video technology to offer direct virtual supervision could still be necessary and appropriate.
In the proposed rule, CMS clarified that direct supervision does not require real-time presence or observation, but instead requires the supervising physician (or other practitioners) to be immediately available to engage via audio/video technology (excluding audio-only). Despite CMS’s flexibility in revising the direct supervision definition, CMS remains concerned that direct supervision through virtual presence may be insufficient to support the PFS payment permanently, due to patient safety issues. Therefore, CMS seeks information from commenters on whether there should be any additional “guardrails” or limitations to ensure patient safety and clinical appropriateness. CMS also seeks information on what risks this policy might introduce to patients as they receive care from practitioners that would supervise care virtually in this way and potential concerns around induced utilization and fraud, waste and abuse, and how those concerns might be addressed.
Payment for Audio-Only Services
The proposed rule also solicits comments on the continuation of payment for audio-only services. In particular, CMS is soliciting comments on whether it should develop coding and payment for a service similar to the virtual check-in but for a more extended unit of time and with an accordingly higher value. It is also seeking input from commentators on the appropriate duration interval for such services and the resources in both work and practice expense that would be associated with furnishing them. Additionally, CMS is looking for comments on whether separate payment for such telephone-only services should be a provisional policy to remain in effect until a year or some other period after the end of the PHE or if it should be a PFS payment policy permanently.
Many providers and patients have benefited from the increased flexibility of audio-only services during the PHE, and the delivery of these services will be interrupted if the PHE ends before CMS has decided whether and how to continue payment for audio-only services. This presents a significant challenge for providers, who will have to consider how to continue providing care to these patients in the absence of payment audio-only services.
Other Proposed Changes Included in the Proposed Rule
In addition to the above proposed changes, the proposed rule:
Co-Authors: Sheila Madhani and Rachel Stauffer from McDermott+Consulting